News | Radiation Therapy | September 27, 2017

MedLever and Hong Kong Sanatorium Partner to Streamline Proton Therapy Workflow

MedLever Platform to enable interoperability for patient setup and imaging process with MR-guided proton treatment delivery

MedLever and Hong Kong Sanatorium Partner to Streamline Proton Therapy Workflow

September 27, 2017 — MedLever Inc. recently announced the launch of a comprehensive agreement with the Hong Kong Sanatorium & Hospital (HKSH) to use the MedLever Platform to enable interoperability and streamline workflow for proton therapy delivery. MedLever and HKSH are working together to develop the information backbone to support the magnetic resonance (MR)-guided proton therapy solution being developed at HKSH. Additionally, MedLever will support the information management needs for conventional patient setup incorporating MR imaging. The solution will be first deployed in the conventional therapy department to enable simplified workflow, effective connectivity and data exchange among multiple systems.

The novel setup room methodology developed by the HKSH and supported by the MedLever Platform improves efficiency and patient throughput. By joining forces, MedLever and the HKSH are building an infrastructure solution to enable interoperability among disparate imaging and therapy modalities including MR, conventional X-ray, computed tomography (CT) and photon/proton treatment delivery systems from several vendors.

Image-guided patient positioning in the setup room using the MedLever Platform improves patient throughput significantly and permits the flexible use of different imaging modalities including MRI. Ben Yu, Ph.D., head, medical physics and research at HKSH stated that “one of the keys of success is the capability to transfer data between setup room, gantry room and the treatment planning system. We are delighted to have MedLever working with us on this project and making MR-guided radiation therapy using the setup room possible.”

“We wanted a vendor that had experience with Mosaiq and demonstrated development flexibility to adapt to our changing needs here at HKSH,” added George Chiu, M.D., head, radiotherapy. “MedLever has demonstrated the willingness to listen and the flexibility to change throughout our pilot project. We look forward to further collaborations between MedLever and HKSH in enhancing our patient care.”

For more information: www.medlever.com

Related Content

Gadolinium-enhanced MRI of a cardiac radiation therapy patient at baseline (left) and 3 months post-treatment (right). Top: the left ventricle with patchy, gadolinium-enhanced scar was transmurally targeted with a radiation ose of 25 Gy between 3 and 6 o’clock (red brackets). Nonenhanced, remote myocardium is adjacent to target region (white arrowhead). Bottom: surviving nonenhanced myocardium within the same images is visible in the targeted region at baseline and 3 months post-treatment (yellow outline).

Gadolinium-enhanced MRI of a cardiac radiation therapy patient at baseline (left) and 3 months post-treatment (right). Top: the left ventricle with patchy, gadolinium-enhanced scar was transmurally targeted with a radiation ose of 25 Gy between 3 and 6 o’clock (red brackets). Nonenhanced, remote myocardium is adjacent to target region (white arrowhead). Bottom: surviving nonenhanced myocardium within the same images is visible in the targeted region at baseline and 3 months post-treatment (yellow outline). See more figures from this study.

Feature | Radiation Therapy | September 28, 2021
September 28, 2021 — New research from Washington University School of Medicine in St.
The global radiotherapy devices market is expected to grow from $5.44 billion in 2020 to $5.848 billion in 2021 at a compound annual growth rate (CAGR) of 7.5%

Varian's Ethos artificial intelligence radiotherapy device.

News | Radiation Oncology | September 28, 2021
September 28, 2021 — The global radiotherapy devices market is expected to grow from $5.44 billion in 2020 to $5.848
Scientists have identified two subtypes of metastatic prostate cancer that respond differently to treatment, information that could one day guide physicians in treating patients with the therapies best suited to their disease.

Getty Images

News | Prostate Cancer | September 24, 2021
September 24, 2021 — Scientists have identified two subtypes of metastatic...
The "Global Surface Guided Radiation Therapy (SGRT) Devices Market, By Device Type (Portable v/s Fixed), By Application (Breast Cancer, Head & Neck Cancer, Abdominal & Pelvic Cancer, Dermatology, Others), By End User, By Region, Competition Forecast & Opportunities, 2026" report

Image courtesy of Varian

News | Radiation Therapy | September 24, 2021
September 24, 2021 — The ...
The National Cancer Institute announced that Virginia Commonwealth University Massey Cancer Center, Medical University of South Carolina Hollings Cancer Center and City of Hope Comprehensive Cancer Center secured a highly competitive Specialized Program of Research Excellence (SPORE) grant that aims to address lung cancer racial disparities through precision medicine, targeted smoking cessation programs and community outreach.

VCU Massey Cancer Center director and SPORE principal investigator Dr. Robert Winn explains how this grant will help combat racial inequities in lung cancer. Image courtesy of VCU Massey Cancer Center

News | Lung Imaging | September 23, 2021
September 23, 2021 — The National Cancer Institute announced tha
The development of new research guidelines for interventional oncology that standardize treatment outcomes and the reporting of data represents a major step forward for an increasingly important medical subspecialty, according to a report in Radiology.

Getty Images

News | Radiation Oncology | September 21, 2021
September 21, 2021 — The development of new research guidelines for interventional oncology that standardize treatmen
Non-oncology doctors’ knowledge of oncology is frequently not up to date, with risks in the communication with patients  

Getty Images

News | Radiation Oncology | September 20, 2021
September 20, 2021 — The rapid pace of developments in the oncology field, mainly brought by cancer immunotherapy, me
IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and SCK CEN (Belgian Nuclear Research Center) announced a strategic R&D partnership to enable the production of Actinimum-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.
News | Radiation Oncology | September 17, 2021
September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, a
Evaluation of therapeutic efficacy of drug candidates in preclinical oncology with positron emission tomography (PET)

Getty Images

Feature | PET Imaging | September 14, 2021 | By Todd Sasser, Ph.D.